Oxazolidinones: A new class of antimicrobials

Infections in Medicine

Volumn 16, Issue 7, 1999, Pages 435-445

  Ford, Charles ^a   Hamel, Judy ^a   Stapert, Douglas ^a   Moerman, Judy ^a   Hutchinson, Douglas ^a   Barbachyn, Michael ^a   Zurenko, Gary ^a  

^a PFIZER INC   (United States)

Author keywords

Bacteria, gram positive; Enterococcus; Linezolid; Oxazolidinone; Streptococcus

Indexed keywords

AMPICILLIN; CLINDAMYCIN; EPEREZOLID; LINEZOLID; OXAZOLIDINONE DERIVATIVE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; CONTROLLED STUDY; CROSS RESISTANCE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; ENTEROCOCCUS FAECALIS; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PROTEIN SYNTHESIS INHIBITION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0032814898     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Slee AM, Wuonola MA, McRipley RJ, et al. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother. 1987;31:1791-1797.
2. Daly JS, Eliopoulos GM, Reiszner E, et al. Activity and mechanism of action of DuP 105 and DuP 721: new oxazolidinone compounds. J Antimicrob Chemother. 1988;21:721-730.
3. Barry AL. In vitro evaluation of DuP 105 and DuP721: two new oxazolidinone antimicrobial agents. Antimicrob Agents Chemother. 1988;32:150-152.
4. Neu HC, Novelli A, Saha G, et al: In vitro activities of two new oxazolidinone antimicrobial agents, DuP 721 and DuP 105. Antimicrob Agents Chemother. 1988;32:580-583.
5. Zajac I, Lam GW, Hoffman HE, et al. Pharmacokinetics of DuP 721, a new synthetic oxazolidinone antibacterial. In: Program and abstracts of the 27th Interscience Conference of Antimicrobial Agents and Chemotherapy; 1987; New York. Abstract 247.
6. Daly JS, Eliopoulos GM, Willey S, et al. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother. 1988;32: 1341-1346.
7. Eustice DC, Feldman PA, Slee AM. The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis. Biochem Biophys Res Commun. 1988;150: 955-971.
8. Eustice DC, Feldman PA, Zajac I, et al. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother. 1988;32: 1218-1222.
9. Brumfitt W, Hamilton-Miller JMT. In vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones. J Antimcrob Chemother. 1988;21:711-720.
10. Brickner SJ, Hutchinson DK, Barbachyn MR, et al. Synthesis and antimicrobial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem. 1996;39:673-679.
11. Brickner SJ. Oxazolidinone antibacterial agents. Curr Pharm Design. 1996;2:175-194.
12. National Committee for Clinical Laboratory Standards. Approved Standard: Methods for Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 3rd ed. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1993.
13. National Committee for Clinical Laboratory Standards. Approved Standard: Methods for Antimicrobial Susceptibility Tests for Anaerobic Bacteria. 3rd ed. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1993.
14. Ford CW, Hamel JC, Stapert D, et al. Establishment of an experimental model of a Staphylococcus aureus abscess in mice by the use of fextran and gelatin microcarriers. J Med Microbiol. 1988;28:259-268.
15. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimirob Agents Chemother. 1996;40:839-845.
16. Zurenko GE, Ford CW, Hutchinson DK, et al. Oxazolidinone antibacterial agents: Development of the clinical candidates eperezolid and linezolid. Expert Opinion Investig Drugs. 1997; 6:151-158.
17. Ford CW, Hamel JC, Wilson DM, et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents against experimental bacterial infections. Antimicrob Agents Chemother. 1996;40:1508-1513.
18. Ford CW, Hamel JC, Stapert D, et al. Oxazolidinones, new antibacterial agents. Trends Microbiol. 1997;5:196-200.
19. Pawsey SD, Daley-Yates PT, Wajszczuk CP, et al. U-100766 safety, toleration and pharmacokinetics after oral and intravenous administration. In: Program and abstracts of the 1st European Congress of Chemotherapy; 1996; Glasgow. Abstract F151.
20. Ford CW, Hamel JC, Stapert D, et al. Therapy of soft tissue infections with linezolid, a new oxazolidinone antibiotic. Chemotherapie J 4. In: Program and abstracts of the German Congress of Infections; 1997; Berlin. Abstract Sy13.4.
21. Andes D, Vesga O, Batts D, et al. Pharmacodynamic activity of an oxazolidinone in an animal infection model. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996; New Orleans. Abstract F233.
22. Buysse JM, Demyan WF, Dunyak DS, et al. Mutation of the AcrAB antibiotic efflux pump in Escherichia coli confers susceptibility to oxazolidinone antibiotics. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996; New Orleans. Abstract C42.
23. Kaatz GW, Seo SM. In vitro activities of oxazolidinone compounds U-100592 and U-100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 1996;40:799-80.
24. Mulazimoglu L, Drenning SD, Yu VL. In vitro activity of two novel oxazolidinones (U-100592 and U-100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 1996;40:2428-2430.
25. Lin AH, Murray RW, Schaadt RD, et al. Oxazolidinones block translation by binding to ribosomes. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996; New Orleans. Abstract C-101.